Janet Wood­cock slams calls for FDA 'fire­wal­l' amid ad­u­canum­ab de­ba­cle, cit­ing need for col­lab­o­ra­tive drug de­vel­op­ment

The FDA has long tak­en a col­lab­o­ra­tive ap­proach to work­ing with drug­mak­ers on ap­proval ap­pli­ca­tions, all in the in­ter­est, it says, of bring­ing the best mol­e­cules to mar­ket. But when the drug is a lemon, the cozy re­la­tion­ship be­tween reg­u­la­tors and in­dus­try courts easy blame.

Could a “fire­wall” be­tween reg­u­la­tors and drug­mak­ers pre­vent lousy drugs from get­ting the agency’s back­ing? Act­ing com­mis­sion­er Janet Wood­cock says no way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER